Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for the quarter ended March 31, 2026.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CARE Ratings Limited has submitted the Q4 FY26 monitoring report for Senores Pharmaceuticals' Rs. 500 crore IPO (December 2024). Of the Rs. 500 crore raised, Rs. 394.98 crore (79%) has been utilized with Rs. 105.02 crore remaining unutilized, parked in fixed deposits with ICICI Bank and HDFC Bank. The Atlanta manufacturing facility project (Rs. 107 crore allocated) shows significant delay—only Rs. 6.98 crore utilized against a scheduled Rs. 40 crore for FY26, with the company citing ongoing geo-political issues and extending completion to FY27. Debt repayment objectives (Rs. 73.10 crore and Rs. 20.20 crore) were completed in Q1FY26 with minor delays. Working capital funding for subsidiaries Ratnatris and SPI was also completed in FY26. No material deviation exceeding 10% was found, though the monitoring agency flagged ongoing delays in one of the IPO objects.
The delay in the Atlanta sterile injections facility project is a concern, leaving Rs. 100+ crore of IPO proceeds unutilized and parked in bank deposits. Shareholders should monitor the revised FY27 timeline, as geo-political factors may continue to impact capital expenditure deployment.